Valeo Pharma (VPH.C) Completes Implementation of New Corporate Structure

Valeo Pharma (VPH.C) announced today that it has completed implementation of its new corporate structure and launched full commercial activities in support of Enerzair Breezhaler triple therapy and Atectura Breezhaler dual therapy, two new asthma medications.

“Our recently completed medical team, headed by Nelly Komari, provides us with strong capabilities for our expanding portfolio of innovative drugs. Redesca^®, Enerzair and Atectura are important launches for us and we expect these three products to lead our sales growth. Launched in April, Redesca has quickly become our fastest growing product line and we continue to believe that it will achieve peak revenues of $30M annually,” said Steve Saviuk, CEO.

The global asthma treatment market is expected to reach a whopping USD$26.01 billion by 2027, expanding at a CAGR of 4.5%. Statistics aside, I would like to think that everyone has at least one friend or family member who has asthma. Hell, there was a time I thought I had asthma because I was incapable of running for more than 5 minutes. Turns out years of smoking will do that to you. When I was still smoking a chimney, I got to experience a fraction of what living with asthma was like. The smallest activities would put my cardiovascular system into overdrive and my lungs felt like they were ready to burst after just a few minutes.

In comparison to someone living with asthma, my experience was trivial. Even if I was out of shape, I at least knew when to expect trouble. On the contrary, those living with asthma are constantly at risk of having an asthma attack due to a variety of triggers, including sinus infections, allergies, chemicals, physical exercise, weather, and food, among several others. Furthermore, With COVID-19 circulating globally, individuals with asthma are now at an even greater risk than before. With this in mind, Atectura and Enerzair are two of Valeo’s marketed asthma treatments. Compared to the current standard of care, both medications have demonstrated that they are able to improve the level of control of asthma symptoms and better prevent the related complications.

“The successful integration of our dedicated sales teams with the related supportive head office functions will create significant operating leverage over the coming years as we continue to add strategic assets to each business unit and take full advantage of our new corporate structure and commercial platform,” said Frederic Fasano, Valeo’s President and Chief Operating Officer.

Following the implementation of Valeo’s new corporate structure, the Company is now divided into two business units, Respiratory and Specialty Products. These units will be led by Howard Wiseman and Jean-Charles Leathead, respectively. Additionally, Valeo’s sales team has expanded to 65 professionals, bringing the Company’s current total of full-time employees to 95. So, what does this mean? Long story short, Valeo’s new corporate structure will improve the Company’s commercialization efforts. In fact, Valeo’s Respiratory business unit has already deployed full commercial coverage across Canada. Keep in mind, asthma is a serious health issue in Canada, currently affecting almost 4 million Canadians. As a result, the Canadian asthma treatment market is estimated at roughly $700 million. With an expansive pipeline of marketed products, including Redesca, Valeo is well positioned to see growth in the future. Moreover, the Company has also expanded its head office and warehouse capacity to support its recent product launches. For a more informative look at Valeo’s portfolio and financials, check out this great article by Joseph Morton.